The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-B59: An open-label, multicenter, phase 1/2 study of efdelikofusp alfa (GI-101A; CD80-IgG4 Fc-IL2v2) in advanced solid tumors (part E & F of GII-101-P101).
 
Jae Lyun Lee
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Eutilex (Inst); GI Innovation (Inst); Janssen (Inst); LG Chem (Inst); Loxo/Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - J INTS BIO; KANAPH Therapeutics Inc.
Consulting or Advisory Role - Cyrus therapeutixs; J Ints Bio; KANAPH Theripeutic Inc
Speakers' Bureau - ASCO; AstraZeneca/MedImmune; ESMO; Guardant Health; IASLC; Korean Cancer Association; Korean Cancer Study Group; Korean Society of Medical Onoclogy; Korean Society of Thyroid-Head and Neck Surgery; MSD; Novartis; Pfizer; Roche; The Chinese Thoracic Oncology Society; Zai Lab
Research Funding - CJ bioscience; Cyrus Therapeutics; Dong-A ST; ImmuneOncia; J Ints Bio; Johnson & Johnson; Ligachem bioscience; MSD; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Byoung Yong Shim
Consulting or Advisory Role - AstraZeneca; J Ints Bio
 
Sang Joon Shin
No Relationships to Disclose
 
Hyo Jin Lee
No Relationships to Disclose
 
Jung-Yun Lee
Honoraria - Abbvie; AstraZeneca; CanariaBio; Corcept Therapeutics; DAIICHI SANKYO; Eisai; Genmab; GII; GlaxoSmithKline; Immunogen; Lilly; Merck Serono; MSD; Pfizer; Regeneron; Seagen; Sutro Biopharma
Consulting or Advisory Role - Abbvie; AstraZeneca; CanariaBio; Corcept Therapeutics; DAIICHISANKYO; Eisai; Genmab; GII; GlaxoSmithKline; Immunogen; Lilly; Merck; MSD; Pfizer; Regeneron; Seagen; Sutro Biopharma
Speakers' Bureau - Abbvie; AstraZeneca; DAIICHI SANKYO; Eisai; GlaxoSmithKline; MSD; Roche; Takeda
Research Funding - Abbvie (Inst); Advenchen Laboratories (Inst); Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); BEONE (Inst); BerGenBio (Inst); BMS (Inst); CanariaBio (Inst); Cellid (Inst); Chong Kun Dang Pharmaceutical (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); DAIICHI SANKYO (Inst); Eisai (Inst); GENEMEDICINE (Inst); Genmab (Inst); GII (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Janssen (Inst); Kelun (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); Novartis (Inst); onconic therapeutics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Sutro Biopharma (Inst); Synthon (Inst); Takeda (Inst); TORL-BIO (Inst); Zymeworks (Inst)
 
John Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Allarity Therapeutics (Inst); Apros Therapeutics; Aptevo Therapeutics (Inst); Arcus Biosciences; Arvinas; Arvinas; Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); Aulos Bioscience (Inst); Axion BioTherapeutics (Instil Bio); BioBank Online (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Bright Peak Therapeutics; Bristol-Myers Squibb; Calico; Cellgene Corp. (Inst); CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corbus Pharmaceuticals (Inst); Corvus Pharmaceuticals; CUE BioPharma (Inst); Cullinan Oncology (Inst); Curis; CytomX Therapeutics; DAAN Biotherapeutics; Duality Biologics; EMD Serono; Engineered BioPharmaceuticals (Inst); Ensem; Exelixis; Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; GI Innovation (Inst); Glenmark Specialty SA (Inst); Harbour BioMed (Inst); I-Mab (Inst); IconOVir Bio (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; MBrace Therapeutics Inc. (Inst); Medikine (Inst); Merck (Inst); Modena TX (Inst); Molecular Templates (Inst); MT Group (Inst); Multitude Therapeutics Inc (Inst); NextCure (Inst); Nuvation Bio (Inst); PBD Biologics LTD (Inst); PEEL Therapeutics (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Qurgen (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Revolution Medicines Inc. (Inst); RiboScience (Inst); Rondo; Sairopa (Inst); Seagen; Sequenom (Inst); Simcere (Inst); SK Life Sciences (Inst); STEMCELL Technologies (Inst); Tasca; Tempest Therapeutics; Terramoto; Teva; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Soohyeon Lee
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - DreamCIS; Takeda
Research Funding - Amgen; ST Cube; Yuhan Co
Travel, Accommodations, Expenses - ST Cube
 
Thomas Marron
Consulting or Advisory Role - Abbvie; Abdera Thereapeutics; AN2; Arrowhead Pharmaceuticals; Astellas Pharma; Avammune; Boehringer Ingelheim; Caris Life Sciences; EMD Serono; Geneos; Merck; Natures Toolbox; Replimune; Storm Therapeutics; Tatum Bioscience
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Nari Yun
Employment - GI Innovation
Leadership - GI Innovation
Stock and Other Ownership Interests - GI Innovation
 
Mina Ham
Employment - GI Innovation
Stock and Other Ownership Interests - GI Innovation
 
Kwang-Soo Shin
Employment - GI Innovation
 
Myoung Ho Jang
Employment - GI Innovation
Leadership - GI Innovation
Stock and Other Ownership Interests - GI Innovation